研究中心展示 Research Center Exhibition

Wu Zuze-Freelymedical Cellular Medicine Research Center

The Wu Zuze - Freelymedical Cellular Medicine Research Center is a national-level cell medicine innovation hub jointly established by Freelymedical Changqing Health Management Group, the Beijing Sanyouli Regenerative Medicine Research Center led by Academician Wu Zuze, and Xuzhou Central Hospital. It focuses on original research, development, and translational application of cellular technologies.

The center is steered by Academician Wu Zuze, renowned as the "Father of Chinese Hematopoietic Stem Cells" and an internationally acclaimed medical scientist. He has achieved numerous "world-firsts" and "China-firsts," garnered multiple national-level science and technology accolades, and earned internationally recognized academic accomplishments. Leveraging clinical resources from a top-tier hospital, the center has established an integrated innovation ecosystem encompassing "research, preparation, and translation." It comprises a core research team of doctoral and master's degree holders, equipped with over 70 internationally advanced devices and nearly 400 GMP-certified cell preparation facilities, alongside a comprehensive quality control system. With the mission of "empowering human health through cellular technology," the center aims to streamline the innovation-translation pipeline, providing precise preventive solutions for sub-health populations, supporting the national regenerative medicine industry in achieving "independence, controllability, and global leadership," and advancing the strategic goals of the Healthy China initiative.

UM-Zhuhai Research Institute - Freelymedical Joint Laboratory

The UM-Zhuhai Research Institute - Freelymedical Joint Laboratory is co-established by the Zhuhai UM Science and Technology Research Institute and Freelymedical International Medical Investment Group. As a core scientific research platform for the University of Macau and Freelymedical International, it undertakes joint research initiatives and drives the translation of scientific outcomes. Located within the "Guangdong-Macao Traditional Chinese Medicine Science and Technology Industrial Park" in the Hengqin Deep Cooperation Zone, the laboratory spans 3,000 square meters and strictly adheres to international GMP standards. It includes cleanrooms at the 10,000-class and 100,000-class levels, comprising 1,000 square meters dedicated to research platforms and 500 square meters for preparation platforms, with the capacity to store millions of biological samples.

The laboratory focuses on precision oncology, stem cells, hepatocytes, bone marrow/blood-activated cells, and organoid research, while also conducting fundamental studies in biotechnology. Leveraging organoid and carbon quantum TISA technologies, it is dedicated to rapidly identifying effective drugs for advanced cancer patients and deciphering drug resistance mechanisms, with the aim of improving patient prognosis. The laboratory demonstrates significant potential for translational outcomes and promising application prospects.

Macau University of Science and Technology - Freelymedical Joint Laboratory

The joint laboratory, co-established by Macau University of Science and Technology and Freelymedical International Medical Group in the Hengqin-Guangdong-Macao Deep Cooperation Zone, is dedicated to creating an innovation benchmark and demonstration platform for the deep integration of industry, academia, research, and clinical application in the field of biomedicine within the Guangdong-Hong Kong-Macao Greater Bay Area.

The laboratory is designed and constructed in strict accordance with international GMP standards. It is equipped with 10,000-class and 100,000-class cleanroom R and D platforms, advanced high-throughput drug screening systems, and a clinical-standard cell preparation center, forming a comprehensive scientific research infrastructure system. The facility focuses on three key cutting-edge areas: precision oncology treatment, stem cell regenerative medicine, and quantum dot diagnostics. By developing highly sensitive labeling and detection systems, it aims to achieve early and precise screening and diagnosis for major diseases such as cancer. Centered on a "research-clinical-industry" closed-loop translation model, the laboratory works to shorten the R and D cycle for innovative drugs and medical devices. By integrating the research strengths of MUST and the industrial resources of Freelymedical, it contributes to building the Greater Bay Area into a hub for biomedical technology innovation, supporting the "Healthy China 2030" strategy.

Tongji University Sino-U.S. Stem Cell Research Center

The Tongji University Sino-U.S. Stem Cell Research Center was jointly established by Tongji University and the University of California, Los Angeles (UCLA). The laboratory is located at Tongji Hospital affiliated with Tongji University in Shanghai, and its R and D team comprises numerous professors and doctors specializing in biomedicine and clinical medicine. It is a national key laboratory certified by the Ministry of Science and Technology and the National Health Commission.

The Sino-U.S. Stem Cell Research Center possesses over ten thousand seed cells derived from various umbilical cord sources. Both the cell donors and their family members undergo rigorous health and genetic screening to ensure the cells are free from issues such as cancer, infectious diseases, and genetic mutations.

The clinical application platform has demonstrated safety and effectiveness. Significant progress has been made in related disciplinary groups and new technologies, including neurological disorders, biological therapies for tumors, combined immunotherapy research, and medical aesthetic repair. The establishment of specialized wards, such as the Biological Therapy Research Center ward, the Spinal Cord Injury Rehabilitation ward, and the Cardiac Rehabilitation unit, has effectively ensured that cutting-edge and interdisciplinary research outcomes are successfully translated into clinical treatments.